



(51) International Patent Classification:

C07K 16/28 (2006.01) *A61K 47/68* (2017.01)
A61P 35/00 (2006.01) *A61K 31/505* (2006.01)
A61P 35/02 (2006.01) *C07K 16/46* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/EP2018/055939

(22) International Filing Date:

09 March 2018 (09.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1703876.1 10 March 2017 (10.03.2017) GB

(71) Applicant: **BERLIN-CHEMIE AG** [DE/DE]; Glienicker
 Weg 125-127, 12489 Berlin (DE).

(72) Inventors: **BINASCHI, Monica**; Menarini Ricerche, Via
 Tito Speri 10 Pomezia, Rome (IT). **BIGIONI, Mario**;
 Menarini Ricerche, Via Tito Speri 10 Pomezia, Rome (IT).
MERLINO, Giuseppe; Menarini Ricerche, Via Tito Speri
 10 Pomezia, Rome (IT). **SIMONELLI, Cecilia**; Menari-
 ni Ricerche, Via Sette Santi 3, Firenze (IT). **BERTONI,**
Francesco; Institute of Oncology Research Fondazione

per la Ricerca e la Cura sui Linfomi, Via Vela 6,
 6500 Bellinzona (CH). **PELLACANI, Andrea**; Menarini
 Ricerche, Via Sette Santi 3, Firenze (IT).


(74) Agent: **DEHNS**; St Bride's House, 10 Salisbury Square,
 London, Greater London EC4Y 8JD (GB).

(81) Designated States (*unless otherwise indicated, for every
 kind of national protection available*): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
 HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
 kind of regional protection available*): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY

Figure 9



(57) Abstract: The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*